comparemela.com
Home
Live Updates
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial | Infectious Diseases | JAMA : comparemela.com
Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial | Infectious Diseases | JAMA
This randomized clinical trial compares the efficacy and safety of letermovir vs valganciclovir prophylaxis for cytomegalovirus (CMV) disease in CMV-seronegativ
Related Keywords
Seattle
,
Washington
,
United States
,
University Of Washington
,
California
,
San Diego
,
American
,
Ajitp Limaye
,
,
Merck Co Inc
,
Merck Co
,
European Medicines Agency
,
American Society Of Nephrology Kidney Week
,
Gilead Sciences
,
Merck Sharp Dohme
,
American Transplant Congress
,
Drug Administration
,
Good Clinical Practice
,
International Conference
,
Harmonization Guideline
,
Secondary Efficacy Outcomes
,
Efficacy Outcomes
,
Size Calculation
,
Efficacy Outcome
,
Interest Disclosures
,
Viiv Healthcare
,
Drs Strizki
,
Merck Sharp
,
Infectious Disease Week
,
American Society
,
Nephrology Kidney Week
,
comparemela.com © 2020. All Rights Reserved.